A prospective, observational grouped analysis to evaluate the effect of triptorelin on lower urinary tract symptoms in patients with advanced prostate cancer.

Gil T, Aoun F, Cabri P, Maisonobe P, van Velthoven R

Therapeutic advances in urology1 Jun 2015Cited by 11 (Europe PMC)

PMID26161142PMCIDPMC4485414DOI10.1177/1756287215574480PepBankPUB-26161142

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

01HumanObservational studyEfficacy outcome
In men with prostate cancer and urinary symptoms, triptorelin treatment was associated with lower IPSS at weeks 24 and 48 than baseline.
In plain wordsMen receiving triptorelin had lower urinary symptom scores at follow-up than baseline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseTotal IPSS
Study
n = 1,282
Analysis
Secondary
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
Dose not stated
Measurements
IPSS
18.2 points
baseline
IPSS
11.9 points
week 24
IPSS
10.6 points
week 48
Source sentences
Summary
Mean total IPSS was reduced from 18.2 [95% confidence interval (CI) 17.8-18.5] at baseline to 11.9 (95% CI 11.5-12.3; p < 0.001) and 10.6 (95% CI 10.2-11.0; p < 0.001) at weeks 24 and 48, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Prospective, noninterventional, multicentre studies of LUTS located in Algeria, Belgium, China, Hungary, Romania and South Korea, in patients who were scheduled to receive triptorelin (3-month extended release or 1-month formulation) in clinical practice.
Summary · context
In total, 2461 patients were recruited in the studies; 1282 patients had moderate or severe LUTS at baseline (IPSS > 7), received triptorelin and had follow-up IPSS.
Report a problemFND-2616114201
02HumanObservational studyEfficacy outcome
In men with prostate cancer, triptorelin treatment was associated with lower PSA at weeks 24 and 48 than baseline.
In plain wordsMen receiving triptorelin had lower PSA at follow-up than baseline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreasePSA
Study
n = 1,282
Analysis
Secondary
Outcome group
Cancer biomarkers and prognosis · Cancer
Studied dose
Dose not stated
Measurements
PSA
117.9 ng/ml
baseline
PSA
8.5 ng/ml
week 24
PSA
16.6 ng/ml
week 48
Source sentences
Summary
Mean PSA levels were reduced from 117.9 ng/ml (95% CI 93.8-141.9) at baseline to 8.5 ng/ml (95% CI 5.2-11.7) and 16.6 ng/ml (95% CI 7.4-25.8) at weeks 24 and 48, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Prospective, noninterventional, multicentre studies of LUTS located in Algeria, Belgium, China, Hungary, Romania and South Korea, in patients who were scheduled to receive triptorelin (3-month extended release or 1-month formulation) in clinical practice.
Summary · context
In total, 2461 patients were recruited in the studies; 1282 patients had moderate or severe LUTS at baseline (IPSS > 7), received triptorelin and had follow-up IPSS.
Report a problemFND-2616114202

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.